학술논문
The Prevention and Treatment of Missing Data in Clinical Trials: An FDA Perspective on the Importance of Dealing With It
Document Type
Academic Journal
Author
Source
Clinical Pharmacology & Therapeutics. Mar 01, 2012 91(3):550-554
Subject
Language
English
ISSN
0009-9236
Abstract
At the request of the Food and Drug Administration (FDA) and with its funding, the Panel on the Handling of Missing Data in Clinical Trials was created by the National Research Councilʼs Committee on National Statistics. This panel recently published a report with recommendations that will be of use not only to the FDA but also to the entire clinical trial community so that the latter can take measures to improve the conduct and analysis of clinical trials.